These findings show that the activation of the NF-κB signaling pathway is the key driver of the occurrence of PCNSL, providing an important theoretical reference for the use of Bruton’s tyrosine kinase (BTK) inhibitors to treat PCNSL. The gene discussed is NFKB1; the disease is primary central nervous system lymphoma.